Navigation Links
Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients
Date:4/28/2009

both groups.

Patients who experienced retrograde ejaculation and those who did not both showed significant improvement (p<.02) compared with patients receiving placebo in IPSS and Qmax after 12 weeks of treatment. Mean improvement in IPSS was greater in men experiencing this side effect than men who did not (-7.2 versus -6.1, p=0.3856) and for Qmax (3.1 mL versus 2.4 mL, p=0.0699).

About RAPAFLO(TM)

RAPAFLO(TM) is an effective, uniquely selective alpha-1 adrenergic receptor antagonist. RAPAFLO(TM) maximizes target organ activity by binding with high affinity to the alpha (1A) receptors concentrated in the prostate. The antagonism of these receptors cause the smooth muscles in these tissues to relax and results in improved urine flow and a reduction in BPH symptoms. The binding affinity for the alpha (1B) receptors that cause smooth muscle in peripheral vessels is significantly lower, which may minimize orthostatic hypotension.

The most common drug-related side effect was retrograde ejaculation. The second most commonly-reported adverse event was dizziness. The incidence of treatment-related dizziness was low and only slightly higher among RAPAFLO(TM) than placebo-treated patients (11 vs. 3 patients).

Previously presented data included information that in clinical trials RAPAFLO(TM) was administered with a single dose of medications for erectile dysfunction in healthy male subjects (N=24) and that there were no reported events of symptomatic orthostatis or dizziness. RAPAFLO(TM) demonstrated no meaningful electro cardiac effects during Phase 3 trials and during thorough QTc testing as required for new chemical entities by the FDA.

RAPAFLO(TM) was originally developed by Kissei Pharmaceutical Co., Ltd. in Japan, where RAPAFLO(TM) is the BPH market leader, and licensed to Watson for the U.S., Canada and Mexico markets. '/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. New Data Presented at AUAs Annual Conference Prove GELNIQUE(TM) (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients
2. NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
3. Mersanas Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
4. Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009
5. 2009 ESCEO-IOF Alliance for Better Bone Health Young Investigator Award presented to Dr. Nick Harvey
6. IADR Oral Medicine and Pathology Research Award presented to UCLA professor
7. Prizes of the Grand Prix MSOO Award Presented in Moscow
8. Pasadena Marathon Presented By Kaiser Permanente Hails Partnership With Tiffany & Co.
9. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
10. Destination Fashion 2009 Presented by Stewart Rahr -
11. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Reinberg HealthDay Reporter FRIDAY, ... common cold sores -- herpes simplex -- might increase the ... In fact, being a carrier of certain antibodies to ... researchers found. "The identification of a treatable cause ... breakthrough," said lead researcher Dr. Hugo Lovheim, an associate professor ...
(Date:10/25/2014)... News) -- A large influx of international aid is ... tens of thousands of deaths from the widening Ebola ... Using a specially designed mathematical model, the researchers ... just one densely populated county of hard-hit Liberia -- ... The researchers said that if international aid isn,t ...
(Date:10/25/2014)... News) -- October,s shorter, darker days can trigger a ... to an expert. People affected by seasonal ... lack motivation and even have trouble getting out of ... said Dr. Angelos Halaris, a professor in the department ... Stitch School of Medicine. "Seasonal affective disorder should ...
(Date:10/22/2014)... Austin, TX (PRWEB) October 22, 2014 ... Criminal Minds featuring skin diseases both fictional ... Foundation (CEHMDF), a nonprofit organization committed to advocacy ... wondering if CBS will take the opportunity to impart ... disease. , There are many misconceptions about ...
(Date:10/22/2014)... For Dr. Iris Hunter, a job is more ... of her life’s mission. Her extensive experience in the nonprofit ... FirstLight HomeCare, make it clear that Hunter’s mission is to ... work makes a difference in the lives of others,” Hunter ... much research, I felt ready to start on this journey ...
Breaking Medicine News(10 mins):Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2
... dropped most pounds went off diabetes meds and ... News) -- Weight loss plays a major role in ... Duke University Medical Center researchers. , Previous studies ... how food is sent from the stomach to the ...
... Help, a patient safety program launched more than ... of UPMC, has significantly improved communication between caregivers ... a review of the program has found. , ... the nation working with the Josie King Foundation ...
... and development collaboration between leading Australian Institutions, the ... University of Melbourne and Bio-Link Partners Ltd., has ... 2008 New Therapy Grant winners. This prestigious research ... is focussed on development and commercialisation of small ...
... Affirms Industry Dominance, DALLAS, June 18 ... the leader in hosted services for email ... processed a record 20,million prescription transactions through ... accredited center. Over 3,200 active,prescribers across eight ...
... to get up from a ... fall safely, ... AEX: PHI) today announced the launch of the website, http://www.LearnNotToFall.com in ... makers of the popular personal,emergency response system, the site features four sections, ...
... today, released a report ,Australian Dementia Research, that recommends ... $36 million in response to the growing economic and ... Prepared by the Dementia Collaborative Research Centre at the ... over the last six years in dementia research was ...
Cached Medicine News:Health News:Weight Loss After Gastric Bypass Is Key to Easing Diabetes 2Health News:Study finds Children's Hospital patient safety program improves caregiver/family communications 2Health News:Dynamin drug discovery team win prestigious international epilepsy grant 2Health News:Dynamin drug discovery team win prestigious international epilepsy grant 3Health News:Zix Corporation Processes More Than 20 Million Electronic Prescriptions 2Health News:Zix Corporation Processes More Than 20 Million Electronic Prescriptions 3Health News:Philips Web Site Offers Seniors and Caregivers Tips and Techniques for Preventing Falls 2Health News:Philips Web Site Offers Seniors and Caregivers Tips and Techniques for Preventing Falls 3Health News:Invest in a future without dementia 2
(Date:10/25/2014)... HOUSTON , Oct. 24, 2014   Metanome, ... of comprehensive metagenomic services and data analysis, was the ... Mass ) Phase I/II clinical trial of SER ... with recurrent Clostridium difficile infections (CDI). ... of Seres Health,s R&D and clinical programs. Such genomic ...
(Date:10/25/2014)... , Oct. 24, 2014 Best ... Medical Affairs leaders with a forum for sharing ... consortium has developed a mechanism for creating and ... leaders discuss key findings from the Medical Affairs ... completed the analysis for the first roundtable of ...
(Date:10/22/2014)... , Oct. 22, 2014  Rescheduling of hydrocodone ... in the pain market, according to a new ... a firm providing market research and consultation exclusively ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... for hydrocodone combination products from Schedule III to ...
Breaking Medicine Technology:Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: